JPRN-UMIN000026730
Unknown
未知
sefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer - FDG-PET/CT and prediction of pembrolizumab in lung cancer
Conditionsadvanced non-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- advanced non-small cell lung cancer
- Sponsor
- Gunma University Hospital
- Enrollment
- 50
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Pregnant woman 2\) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X\-ray. 3\) Patients with collagen vascular disease or autoimmune diseases 4\) Other cases attending physician it is determined unsuitable for registration of the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after anti-PD-1 antibody in patients with previously treated advanced non-small cell lung cancer: a multi-institutional studyPreviously treated advanced non-small cell lung cancerJPRN-UMIN000031009Gunma University120
Recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancerPreviously treated advanced non-small cell lung cancerJPRN-UMIN000020814Gunma30
Completed
Not Applicable
sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot studyadvanced and recurrent non-small cell lung cancerJPRN-UMIN000031095Kansai Medical University30
Active, not recruiting
Not Applicable
se of the PET-Scan examination in the evaluation of the treatment of patients diagnosed with Head and Neck CancerScamous Cell- Carcinoma of Head and NeckNeoplasmsPositron Emission Tomography Computed TomographyC04.557.470.200.400E01.370.350.350.800.700.500RBR-9wwstdAC Camargo Cancer Center
Recruiting
Phase 1
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)Metastatic breast cancerTherapeutic area: Diseases [C] - Neoplasms [C04]Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]CTIS2023-506550-20-00Odense University Hospital30